The design is a prospective, observational (non-interventional) registry for adolescent and adult subjects with NSV under the care of a dermatology provider.

The objective of the registry is to create a cohort of adult and adolescent nonsegmental vitiligo (NSV) subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for NSV. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of NSV, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.

Inclusion Criteria:

Individuals are eligible for enrollment if they meet all of the following criteria:

• Have a dermatologist- or qualified dermatology practitioner-confirmed diagnosis of nonsegmental vitiligo (NSV).

• Is at least 12 years of age or older at the time of enrollment.

• Is willing and able to provide informed consent or assent, with parent/legal guardian consent as applicable.

• Adult participants are willing and able to provide required personal information

  • Full legal name, sex, date of birth, and home ZIP/postal code

• Meet the criteria for one of the following enrollment cohorts at the time of enrollment:

Cohort 1: Eligible Medication Initiators - Individuals initiating a prescribed eligible NSV medication at the time of enrollment.

Cohort 2: Not Initiating Eligible Medication - Individuals not currently receiving NSV medication at the time of enrollment, Individuals receiving eligible NSV medication prior to enrollment.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in the registry:

- Is participating or planning to participate in a blinded clinical trial for a vitiligo therapy.

Subjects enrolled in this registry will be treated according to routine clinical care; the assignment of subjects to any treatment will not be determined in advance by the protocol and will be clearly separated from the decision to include subjects in the registry